The failure of a high-profile clinical trial to treat Alzheimer’s disease means that the biotech market is about to get a big test. But Axovant’s stock meltdown is unlikely to spread.
from WSJ.com: Markets http://ift.tt/2jZTxbB
via https://ifttt.com/ IFTTT
No comments:
Post a Comment